Skip to content

Matteo Buonarroti

3 papers in the library · 3 citations · publishing 2025-2026

Papers

Sort Most recent Most cited

Patterns of Psychedelic Use in Italy: Insights from the Global Psychedelic Survey

Clinical Neuropsychopharmacology and Addiction September 1, 2026 Beatrice Dal Bianco, Matteo Buonarroti, Alessandro Lo Jacono et al.

Background: Epidemiological data on psychedelic use in Italy is limited. In this study, Italian responders in the Global Psychedelic Survey 2025 were subanalyzed to describe patterns of use, motivations, subjective experiences, and health correlates. Methods: Adults (≥21 years) with lifetime psychedelic exposure, residing in or born in Italy or San Marino, were surveyed in a web-based,...

Psychedelics for treatment of negative symptoms and depressive symptoms in schizophrenia spectrum disorder: A narrative review

Schizophrenia Research March 13, 2026 Michel Sabé, Paul Grof, Nathan Sackett et al. 1 citation

Serotonergic psychedelics are re-emerging as therapeutic candidates across psychiatry, particularly for treatment-resistant depression. Their rapid and sustained antidepressant effects, alongside evidence for neuroplastic, dopaminergic, and glutamatergic modulation, have prompted interest in whether they could address depressive and negative symptoms in schizophrenia spectrum disorders (SSDs)....

Microdosing Psychedelics to Restore Synaptic Density in Schizophrenia.

International Journal of Molecular Sciences September 14, 2025 Jacopo Sapienza, Marco Spangaro, Stefano Comai et al. 2 citations

Schizophrenia is a highly polygenic disease, and several genetic variants associated with the disease converge on altered synaptic homeostasis. In particular, the gene encoding complement component 4 (C4) showed the strongest association with schizophrenia, and this protein is involved in complement-dependent and microglia-mediated synaptic pruning. As a matter of fact, microglia are overactive...